GVR Report cover Endocrine Testing Market Size, Share & Trends Report

Endocrine Testing Market Size, Share & Trends Analysis Report By Test Type (hCG, FSH, TSH, Insulin), By Technology (Mass Spectroscopy, Immunoassay), By End-user, And Segment Forecasts, 2022 - 2030

  • Report ID: 978-1-68038-862-6
  • Number of Pages: 180
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2020
  • Industry: Healthcare

Report Overview

The global endocrine testing market size was valued at USD 2,355.4 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 8.31% from 2022 to 2030. The prevalence of diabetes, thyroid, and obesity worldwide has resulted in government funding initiatives for increasing research activities and rapid technological developments caused launch of multiple detection tests as well as novel products by life science companies. The increase in research and development (R&D) in medical and clinical diagnostics’ field, the availability of advanced technologies such as biosensors and point-of-care to cater to the growing awareness of routine health monitoring are few factors attributing to the endocrine testing market growth.

U.S. endocrine testing market size, by technology, 2020 - 2030 (USD Billion)

The endocrine testing market observed a moderate growth in the beginning of COVID-19 pandemic due to the widespread testing for detection of the SARS-CoV2 and research centered towards development of tools for detection. As a result, there was a substantial decrease in endocrine testing and research activities, furthermore closure of laboratories added to reduction in testing. However, the aim towards understanding the COVID-19 infection and the known role of thyroid hormone in immune response regulation led the researchers to study thyroid function in COVID-19 patients.

For instance, researchers from Indonesia published in an article in October 2021, that they conducted a meta-analysis study by including 31,339 patients from 21 studies. In their systemic review, the researchers came to a conclusion that the risk of COVID-19 increased in patients with age & thyroid abnormalities and even resulted in poor treatment outcomes. This understanding revived the routine endocrine testing over the last year due to long-terms effects of COVID-19 infection in the survivors and is even expected to advance the market during forecasted period. 

The demand for endocrine testing is rising as there is increased health consciousness and a growing prevalence of lifestyle diseases among the adult individuals. This upsurge in awareness has contributed to increase of home healthcare and point-of-care (POC) devices with faster and efficient outputs. The home healthcare & POC devices are easy to operate and are cost effective alternatives targeting the adult as well the increasing geriatric population. According to the International Diabetes Federation, 537 million people are already living with diabetes in 2021, and this number is projected to shoot to 643 and 783 million by 2030 and 2045 respectively. These disease projections will directly impact the endocrine testing market and will result in a dramatic growth in the years to come.

With the growing diseased population, the number of tests employed for endocrinology has organically increased. This increase necessitated the need of many new technological advancements for faster and reliable results. For instance, the coupling of mass spectroscopy with liquid chromatography (LC/MS) or tandem mass spectrometry (MS/MS) provides results with better precision and accuracy. Moreover, companies like Agilent Technologies, Inc. are also focusing on developing new alternative technologies for analysis, such as use of LC-ICP-MS for more robust thyroid hormone testing. Such technological developments create huge opportunities for the existing & emerging players, and are expected to fuel the endocrine testing market growth tremendously.

However, the lack of skilled & trained professionals limits the accurate diagnosis restricts the market growth. As endocrine function testing requires sample handling & preparation stages, this necessitates skilled as well as technical expertise. The lack of technically strong personnel eventually limits the quality of endocrine testing and results in poor patient outcomes.

Test Type Insights

The human Chorionic Gonadotropin (hCG) hormone test dominated the endocrine testing market in 2021. High number of easy to use self-test pregnancy kits and need of quantitative estimation of hCG at hospitals or laboratories is contributing to the hCG test’s growth. Moreover, determination of hCG levels to detect abnormalities during different stages of pregnancy along with the growing number of fertile female population is also propelling the revenue generation of this segment. Furthermore, the role of hCG in treatment of infertility in both men & women will also drives the growth in endocrine testing market.   

Additionally, TSH testing also generated significant revenue in 2021. TSH is a key regulator in immune response and is also associated in maintaining multiple hormone levels such as progesterone, hCG among others within the human body. These afore-mentioned roles of TSH along with prevalence of thyroid ailments such as cancer drives the market growth for TSH testing. As per Cancer.Net, it is estimated that in 2022 more than 43,500 adults will be diagnosed with thyroid cancer in the U.S.

The insulin testing is expected to demonstrate a fastest growth rate of 9.81% in the forecast period. Studies from scientists have also demonstrated the fact that thyroid dysfunction and diabetes are the most frequently occurring endocrine disorders which has a large effect on cardiovascular health. As per a scientific article published in December 2021 by the researchers from the Qatar University, it was observed that the occurrence of thyroid disorders are more prevalent in diabetic patients ranging from 9% to even 48%. Also, the researchers concluded that this prevalence was even higher for women (about 32%) than in men in a diabetic population. Such statistics will determine and fuel the insulin testing market in the future.

Technology Insights

In 2021, immunoassay based detection techniques generated a significant revenue of USD 970.7 million in the endocrine testing market. This is due to the presence of multiple instruments and analyzers which uses different types of immunoassay technologies for detection. Also, the presence of immunoassay based tests panel for endocrine and reproductive function offered by many key players further contributes to the highest revenue generation of the segment.

On the contrary, owing to the advancements in technology since past few years, novel methods have been developed for hormone tests. Methods such as mass spectroscopy, chromatography, and nucleic acid based detection methods are taking over and providing accurate and precise results with a shorter turnaround time for endocrine testing panels. Furthermore, coupling of methods such as mass spectrometry with liquid chromatography offers consistent results and overcomes the drawbacks of traditional methods such as cross-reactivity.

End-user Insights

Based on end-user, commercial laboratories held the largest market share of 47.21% in 2021. The availability of variety of tests panels and feasibility of at home collection services is boosting the revenue generation of this segment. Furthermore, commercial laboratories are also expected to observe the fastest growth in forthcoming years. This can be considered due to the growing health consciousness among individuals and the continuous endocrine testing to monitor existing disease and control the predisposed hereditary conditions. Also, the availability of reports over digital platforms by these commercial settings furthers their growth trajectory. For example, Laboratory Corporation of America Holdings or LabCorp, a U.S. based diagnostics company in February 2022 launched a digital portal allowing online orderings of tests and subsequently in April 2022, the company also launched a diagnostic test collection services at home.

Global endocrine testing market share, by end-user, 2021 (%)

In addition, hospitals also observed some market relevance in 2021, as they’re the center for disease identification as well as further treatment. The increased availability of endocrine testing at hospitals and the prognosis by the help of medical professionals are factors attributable for the segment’s share. 

Regional Insights

North America held the largest market share in the endocrine testing market with a share of 45.34% in 2021. This can be attributed to factors such as the high number of diabetic and obese population, affordable & accessible options due to presence of reimbursing bodies, government funding initiatives for the betterment of healthcare settings, as well as the availability of multiple diagnostic companies. For example, the American Thyroid Association, an organization dedicated to support research for treatment of thyroid diseases has funded over USD 2.8 million across 105 grants since the inception of its funding program. Additionally, the presence of key players in this region drives the competition and results in multiple product offerings in the endocrine testing market.

Endocrine Testing Market Trends by Region

From the past decades, factors such as developing medical & diagnostics industry, better healthcare systems, prevalence of disease among the geriatric population and growing personal healthcare expenditure have resulted in fueling the demand for routine endocrine testing in the Asia Pacific. Besides this, the APAC region is also observing growing research activities towards understanding of diseases leading to better disease diagnosis & treatment. All this will result in a significant growth and causes Asia Pacific to exhibit the fastest CAGR.

Key Companies & Market Share Insights

The endocrine testing market has witnessed increasing competition due to various new product launches such as instruments, kits, tests panels as well as development of new technologies for detection of hormone levels. For example, in August 2020, DiaSorin S.p.A announced that it has launched, LIAISON Testosterone xt test with CE marking. This test will be compatible with the company’s instrument, LIAISON XL for endocrine assay development to detect hypogonadism as well as hyperandrogenism. This launch also furthered DiaSorin’s existing endocrine and fertility panel of tests. Such initiatives will keep driving the endocrine testing market and increase the market competition. Some of the prominent key players in the global endocrine testing market include:

  • Abbott Laboratories

  • AB Sciex

  • Agilent Technologies Inc.

  • bioMerieux SA

  • Bio-Rad Laboratories Inc.

  • DiaSorin S.p.A.

  • F. Hoffmann-La Roche Ltd.

  • Laboratory Corporation of America Holdings

  • Quest Diagnostics Incorporated

  • Ortho Clinical Diagnostics

Endocrine Testing Market Report Scope 

Report Attribute


Market size value in 2022

USD 2,534.8 million

Revenue forecast in 2030

USD 4.79 billion

Growth rate

CAGR of 8.31% from 2022 to 2030

Base year for estimation


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million, CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Test type, technology, end-user, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; South Korea; Australia; Brazil; Mexico; South Africa; UAE; Saudi Arabia

Key companies profiled

Abbott Laboratories; AB Sciex; Agilent Technologies Inc.; bioMerieux SA, Bio-Rad Laboratories; DiaSorin S.p.A.; F.Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Ortho Clinical Diagnostics;

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Endocrine Testing Market Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global endocrine testing market report based on test type, technology, end-user, and region:

Global Endocrine Testing Market Segmentation

  • Test Type Outlook (Revenue, USD Million, 2018 - 2030)

    • Estradiol (E2) Test

    • Follicle Stimulating Hormone (FSH) Test

    • Human Chorionic Gonadotropin (hCG) Hormone Test

    • Luteinizing Hormone (LH) Test

    • Dehydroepiandrosterone Sulfate (DHEAS) Test

    • Progesterone Test

    • Testosterone Test

    • Thyroid Stimulating Hormone (TSH) Test

    • Prolactin Test

    • Cortisol Test

    • Insulin Test

    • Others

  • Technology Outlook (Revenue, USD Million, 2018 - 2030)

    • Mass Spectroscopy

    • Immunoassay

    • Chromatography

    • Nucleic Acid Based

  • End-user Outlook (Revenue, USD Million, 2018 - 2030)

    • Hospitals

    • Commercial Laboratories

    • Ambulatory Care Centers

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa (MEA)

      • South Africa

      • UAE

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon